WTX-607, an oral small molecule being developed by Wavebreak, binds to and blocks the formation of small alpha-synuclein protein…
Articles by Michela Luciano, PhD
People diagnosed with Parkinson’s disease in their 80s were significantly more likely to show evidence of brain buildup of…
Researchers have shed light on how alpha-synuclein oligomers, small soluble protein clusters linked to Parkinson’s disease, may disrupt nerve…
Neu Health said it’s joining an incubator program that will help it expand its flagship product, a smartphone app…
Researchers have uncovered how exposure to a common environmental pesticide may disrupt brain function in ways that contribute to…
Prescribing medication for Parkinson’s disease is not straightforward, but instead is influenced by a wide range of factors and…
Suppressing the immune system to reduce brain inflammation, a known contributor to Parkinson’s disease progression, may offer a promising…
Crexont, an extended-release oral formulation of carbidopa and levodopa, significantly improved sleep quality in people with Parkinson’s disease.
U.S. researchers have identified a novel way to block a protein known as DLK, or dual leucine-zipper kinase, that may…
Pretzel Therapeutics has launched a Phase 1 clinical trial to study PX578, a therapy designed to boost the function…